Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Rated “Moderate Buy” by Wall Street Brokerages

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) has been assigned an average rating of “Moderate Buy” from the five ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $3.83.

Several equities analysts recently issued reports on the stock. Weiss Ratings downgraded shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Roth Capital assumed coverage on shares of Nautilus Biotechnology in a research note on Tuesday. They issued a “buy” rating and a $3.50 target price for the company. Zacks Research raised Nautilus Biotechnology to a “hold” rating in a research note on Wednesday. Finally, Leerink Partners initiated coverage on shares of Nautilus Biotechnology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $4.00 price target for the company.

Institutional Trading of Nautilus Biotechnology

Large investors have recently bought and sold shares of the business. TD Waterhouse Canada Inc. increased its position in shares of Nautilus Biotechnology by 1,500.0% during the second quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock worth $29,000 after acquiring an additional 15,000 shares in the last quarter. CTC Alternative Strategies Ltd. bought a new position in shares of Nautilus Biotechnology during the first quarter worth about $48,000. Callan Family Office LLC bought a new stake in Nautilus Biotechnology in the 2nd quarter valued at approximately $49,000. Squarepoint Ops LLC acquired a new stake in shares of Nautilus Biotechnology in the second quarter valued at approximately $63,000. Finally, AXQ Capital LP bought a new position in Nautilus Biotechnology in the second quarter valued at $64,000. 50.71% of the stock is owned by institutional investors.

Nautilus Biotechnology Trading Up 10.6%

NASDAQ NAUT opened at $1.57 on Friday. Nautilus Biotechnology has a 1-year low of $0.82 and a 1-year high of $4.31. The company has a market capitalization of $199.78 million, a price-to-earnings ratio of -3.49 and a beta of 0.73. The stock’s 50 day moving average is $1.01 and its two-hundred day moving average is $2.01.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its earnings results on Monday, July 27th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.10 million. On average, analysts predict that Nautilus Biotechnology will post -0.52 earnings per share for the current year.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to help researchers study the proteome—the complete set of proteins produced by a biological system—with greater sensitivity, accuracy and throughput than conventional methods.

The company’s core offering is the Nautilus Protein Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and may support applications in drug discovery, biotechnology research, academic studies and the development of precision medicine.

Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington.